Medicamen Biotech Announces Audited Results for FY 2025-2026; Recommends Final Dividend
Medicamen Biotech Limited announced key outcomes of its Board of Directors meeting on May 27, 2026. The company released the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026.The Board meeting approved several material actions, including the recommendation of a Final Dividend and the appointment of new professional auditors for the ensuing financial year.
Key Approvals and Recommendations
The Board of Directors approved the following resolutions:- Final Dividend Recommendation: The company recommended the payment of a Final Dividend of Rs. 1.00 (Rupees One Only) per Equity Share, which has a face value of Rs. 10.00 (Rupees Ten Only) each, for the financial year ended March 31, 2026. This is subject to shareholder approval at the Annual General Meeting.
- Statutory Audit Opinion: The statutory auditors, M/s Rai Qimat & Associates, issued their audit reports on the audited consolidated and standalone financial statements and results for the quarter and financial year ended March 31, 2026, with an unmodified opinion.
- Auditor Appointments:
* M/s Cheena & Associates was approved as the Internal Auditor for the financial year 2026-27.
Financial Performance Highlights
The audited financial statements provide a detailed view of the company's performance through March 31, 2026, compared to the previous year.For the period ended March 31, 2026, the company reported the following consolidated financial figures:
| Metric | 31.03.2026 (Amount Rs. Lacs) | 31.03.2025 (Amount Rs. Lacs) |
|---|---|---|
| Total Assets | 37,198.84 | 29,715.05 |
| Total Equity & Liabilities | 37,198.84 | 29,715.05 |
| Revenue from Operations (Total) | 20,088.29 | 16,879.10 |
| Net Profit (Loss) from Continuing Operations | 979.64 | 655.57 |
Consolidated Financial Statements Summary
The company provided detailed comparative statements for its key financial parameters for the year ended March 31, 2026, versus March 31, 2025.Consolidated Balance Sheet (as at March 31, 2026)
| Particulars | 31.03.2026 (Amount Rs. Lacs) | 31.03.2025 (Amount Rs. Lacs) |
|---|---|---|
| Total Non Current Assets | 14,825.43 | 13,260.11 |
| Total Current Assets | 22,373.41 | 16,454.94 |
| TOTAL ASSETS | 37,198.84 | 29,715.05 |
| Share Capital | 1,366.28 | 1,271.46 |
| Other Equity | 26,198.72 | 20,033.84 |
| Total Non Current Liabilities | 851.88 | 593.57 |
| Total Current Liabilities | 8,791.96 | 7,816.18 |
| TOTAL EQUITY & LIABILITIES | 37,198.84 | 29,715.05 |
Consolidated Profit and Loss Account (for the period ended March 31, 2026)
| Particulars | 31.03.2026 (Amount Rs. Lacs) | 31.03.2025 (Amount Rs. Lacs) |
|---|---|---|
| Total Revenue | 20,088.29 | 16,879.10 |
| Total Expense | 18,889.85 | 15,891.10 |
| Profit before exceptional items and tax | 1,198.44 | 988.00 |
| Profit for the period from continuing Operations | 979.64 | 655.57 |
| Earnings per equity share: Basic & Diluted | 7.22 | 5.16 |
Consolidated Cash Flow Statement (for the year ended March 31, 2026)
| Particulars | 31.03.2026 (Amount Rs. Lacs) | 31.03.2025 (Amount Rs. Lacs) |
|---|---|---|
| Operating profit before working capital changes | -173.91 | -50.73 |
| Net cash flow from operating activities | -3,317.23 | -200.00 |
| Net cash flow from investing activities | -285.28 | -172.03 |
| Net cash flow from financing activities | 6,371.58 | -1,364.04 |
| Net increase in cash and cash equivalents | 3,126.42 | 375.94 |
| Cash and cash equivalents at the end of year | 3,108.40 | 358.03 |
MEDICAMEQ Stock Price Movement
Today, Medicamen Biotech Limited shares edged higher, gaining 5.09% to close at ₹284.6. The equity saw brisk trading activity through the day, with a total volume of 69,893 shares recorded.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.